Cosibelimab

Name: Cosibelimab
Creator: U.S. Department of Health & Human Services
Published: 2026-03-14T09:02:58+08:00

data.gov2026-03-14 收录

PD-L1抑制剂

癌症免疫治疗

数据链接：

https://catalog.data.gov/dataset/cosibelimab 数据链接链接失效反馈

官方服务：

资源简介：

UNLOXCYT (cosibelimab) is a monoclonal antibody that blocks PD-L1 to help the immune system fight cancer cells. It's given as an intravenous injection, with each vial...

提供机构：

U.S. Department of Health & Human Services

Notch Signaling and Efficacy PD-1/PD-L1 Blockade in Relapsed Small Cell Lung Cancer

癌症免疫治疗

生物标志物

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine (NE) cancer that accounts for approximately 15% of all lung cancer, with an annual incidence of more than 34,000 in the United State

NIAID Data Ecosystem10

Discovery of Highly Active Kynureninases for Cancer Immunotherapy through Protein Language Model

癌症免疫治疗

活性预测

File Description Fig2_raw_data.xlsx: An Excel file containing raw data for Fig2. training_seqs.fasta: A fasta file used to train regression models. The number next to the accession is kcat/Km. no

Zenodo2024-01-16 更新00

Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

癌症免疫治疗

细胞表观遗传学

To investigated how Matr3 KO affected the function of CD4 T cells We then performed gene expression profiling analysis using data obtained from RNA-seq of Jurkat T cells knocked out of Matr3 or not. O

NIAID Data Ecosystem00

Transcriptomic analysis of Ovarian Cancer Progression and Treatment (combination of Pembrolizumab with Bevacizumab and Metronomic Cyclophosphamide) Response: Identifying DEGs and Pathways Across the Three Time Points.

癌症免疫治疗

生物标志物研究

The three drugs have shown to enhance the immune response against cancer cells giving pembrolizumab, bevacizumab, and cyclophosphamide together work better in treating patients with recurrent ovarian

Harvard Dataverse2023-12-12 更新00

Enhancing the anti-tumor efficacy of Bispecific T cell engagers via cell surface glycocalyx editing

癌症免疫治疗

T细胞工程

Bispecific T-cell engager (BiTE)-based cancer therapies that activate the cytotoxic T cells of a patient’s own immune system have gained momentum with the recent FDA approval of Blinatumomab for treat

NIAID Data Ecosystem00

Cosibelimab

资源简介：

相关数据集